enGene Inc. (ENGN)
NASDAQ: ENGN
· Real-Time Price · USD
8.80
0.00 (0.00%)
At close: Oct 16, 2025, 3:59 PM
8.80
0.00%
After-hours: Oct 16, 2025, 04:10 PM EDT
0.00% (1D)
| Bid | 8.49 |
| Market Cap | 450.49M |
| Revenue (ttm) | 480K |
| Net Income (ttm) | -43.09M |
| EPS (ttm) | -1.9 |
| PE Ratio (ttm) | -4.63 |
| Forward PE | -3.7 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 9.48 |
| Volume | 298,098 |
| Avg. Volume (20D) | 236,473 |
| Open | 8.80 |
| Previous Close | 8.80 |
| Day's Range | 8.49 - 9.29 |
| 52-Week Range | 2.65 - 11.00 |
| Beta | -0.26 |
| Ex-Dividend Date | n/a |
About ENGN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ENGN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ENGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts8 months ago
+1.19%
EnGene Holdings shares are trading higher after Pi...
Unlock content with
Pro Subscription
2 weeks ago · businesswire.com
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity...
2 weeks ago · businesswire.com
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical OfficerBOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc...
